Princeton-based Certara, a drug development company, announced on Thursday that it appointed William Feehery as its new CEO and a member of the board of directors, effective June 3.
Feehery joins Certara from DuPont, where he has served as president of DuPont Industrial Biosciences since 2013. Feehery also serves as a board member for West Pharmaceutical Services, a manufacturer of packing components and delivery systems for pharmaceutical, biotech and medical device companies.
Edmundo Muniz, who has served as Certara CEO since June 2014, will become a member of the Certara board and chair of the board’s newly-formed Science Committee.
“We are very pleased to welcome Bill to Certara. Bill’s broad and diverse background in technology and commercial operations position him well to lead the company. We are confident that his technical, operational and commercial expertise will serve him well as he takes the company to its next level of growth,” said Sheri McCoy, Certara chairman of the Board in a statement.
“We also want to thank Edmundo for the great work he has done in establishing the vision and strategy that has resulted in Certara becoming the world leader in model-informed drug development and a critical innovator in modeling and simulation,” said McCoy.
“I am excited to join Certara, an exceptional company that is reducing the cost, time, and risk of drug development. I could not have made a better choice than to join the company at this exciting time in its growth trajectory,” said Feehery.
He added, “Certara’s track record for optimizing drug development and patient care decision-making by leveraging its integrated portfolio of quantitative and in silico capabilities is impeccable. The company has already had a significant positive impact, helping to bring safer and more effective new therapies to market efficiently. The healthcare field is ripe for accelerated innovation of this type and Certara is poised to lead the market.”